ArticleMolecular and cellular biochemistry2026
AURKA modulates tight junction functionality to influence the proliferation and metastasis of lung adenocarcinoma.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated genome-wide high-throughput screening and functional validation identifies Sm proteins as essential splicing regulators for gastric cancer progression.Functional & integrative genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Aberrant overexpression of AURKA (aurora kinase A) is strongly associated with various malignancies. However, limited research exists regarding its clinical significance and pathogenic mechanisms in lung adenocarcinoma. This study elucidates clinical correlations and provides experimental evidence supporting AURKA's potential as a therapeutic target for lung adenocarcinoma (LUAD). We analyzed AURKA expression levels and prognostic value using data from TCGA and GEO databases. qRT-PCR compared AURKA expression in LUAD tissues and adjacent normal specimens. siRNA-mediated knockdown efficiency was verified through western blotting and qRT-PCR. Cellular proliferation was assessed via CCK-8 assays and tumor ball assay, while migration capacity was evaluated using transwell chambers. Flow cytometry analyzed cell cycle progression and apoptosis. Phosphoproteomic sequencing identified downstream pathways, with western blot validation of key targets. The changes of tight junctions were observed by transmission electron microscopy, fluorescein isothiocyanate dextran 4 kDa (FD4) permeation experiment and immunofluorescence. A subcutaneous xenograft model in nude mice evaluated AURKA's in vivo tumorigenic effects. Our work illustrated that Elevated AURKA expression correlated significantly with poor LUAD prognosis. AURKA silencing markedly suppressed A549 cell proliferation and migration capacity while inducing G2/M phase arrest and apoptosis. Phosphorylated protein sequencing shows that AURKA knockdown is closely related to Cortactin (CTTN) mediated tight junction. Meanwhile, Xenograft models demonstrated that AURKA knockdown substantially inhibited tumor growth and metastatic progression. It was concluded that AURKA serves as a prognostic biomarker in LUAD. Mechanistically, AURKA promotes tumor progression through Cortactin phosphorylation-mediated tight junction disruption. Our findings establish AURKA inhibition as a promising therapeutic strategy for LUAD management.
Indexed as
Identifiers
41201786What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.